Basilea Pharmaceutica Ltd has partnered its Phase 3 antifungal agent, isavuconazole, with Astellas Pharma Inc of Japan, making it eligible for an upfront payment of CHF75 million (€51 million). ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
